Yüksel Ürün, Professor of Medical Oncology at Ankara University School of Medicine, shared Paolo Tarantino’s, Vivian Saykaly Visiting Professor in Medical Oncology at McGill University Health Centre, Clinical Research Fellow at Dana-Farber Cancer Institute, post on X, adding:
“Same class ≠ same drug. Same target ≠ same outcome.
SERENA-4 is another reminder of why we need clinical trials: in medicine, biological plausibility is a hypothesis.
Evidence is the answer.
In oncology, ‘it should work’ is never enough.”
Quoting Paolo Tarantino’s post:
“BREAKING: SERENA-4 is negative.
Similar to giredestrant, camizestrant did not improve outcomes vs AI when combined to CDK4/6i in the 1L setting. Its role remains confined to pts with ESR1 mutations, which seems to be the sweet spot for oral SERDs in MBC.
You can also read: SERENA-4 Phase III Trial Misses Primary PFS Endpoint for Camizestrant Plus Palbociclib in First-Line Advanced Breast Cancer
